193 related articles for article (PubMed ID: 1348448)
1. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.
Hendricks CB; Rowinsky EK; Grochow LB; Donehower RC; Kaufmann SH
Cancer Res; 1992 Apr; 52(8):2268-78. PubMed ID: 1348448
[TBL] [Abstract][Full Text] [Related]
2. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.
Yang CJ; Horton JK; Cowan KH; Schneider E
Cancer Res; 1995 Sep; 55(18):4004-9. PubMed ID: 7664272
[TBL] [Abstract][Full Text] [Related]
3. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864).
Mattern MR; Hofmann GA; McCabe FL; Johnson RK
Cancer Res; 1991 Nov; 51(21):5813-6. PubMed ID: 1657371
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
Rowinsky EK; Adjei A; Donehower RC; Gore SD; Jones RJ; Burke PJ; Cheng YC; Grochow LB; Kaufmann SH
J Clin Oncol; 1994 Oct; 12(10):2193-203. PubMed ID: 7931489
[TBL] [Abstract][Full Text] [Related]
5. Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines.
Vanhoefer U; Müller MR; Hilger RA; Lindtner B; Klaassen U; Schleucher N; Rustum YM; Seeber S; Harstrick A
Br J Cancer; 1999 Dec; 81(8):1304-10. PubMed ID: 10604726
[TBL] [Abstract][Full Text] [Related]
6. Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells.
Traganos F; Kapuscinski J; Gong J; Ardelt B; Darzynkiewicz RJ; Darzynkiewicz Z
Cancer Res; 1993 Oct; 53(19):4613-8. PubMed ID: 8402636
[TBL] [Abstract][Full Text] [Related]
7. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148
[TBL] [Abstract][Full Text] [Related]
8. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells.
Nakagawa M; Schneider E; Dixon KH; Horton J; Kelley K; Morrow C; Cowan KH
Cancer Res; 1992 Nov; 52(22):6175-81. PubMed ID: 1358431
[TBL] [Abstract][Full Text] [Related]
9. Role of differential drug uptake, efflux, and binding of etoposide in sensitive and resistant human tumor cell lines: implications for the mechanisms of drug resistance.
Politi PM; Sinha BK
Mol Pharmacol; 1989 Mar; 35(3):271-8. PubMed ID: 2564628
[TBL] [Abstract][Full Text] [Related]
10. Binding of an optically pure photoaffinity analogue of verapamil, LU-49888, to P-glycoprotein from multidrug-resistant human leukemic cell lines.
Qian XD; Beck WT
Cancer Res; 1990 Feb; 50(4):1132-7. PubMed ID: 1967551
[TBL] [Abstract][Full Text] [Related]
11. RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I.
Buckwalter CA; Lin AH; Tanizawa A; Pommier YG; Cheng YC; Kaufmann SH
Cancer Res; 1996 Apr; 56(7):1674-81. PubMed ID: 8603419
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein-independent mechanism of resistance to VP-16 in multidrug-resistant tumor cell lines: pharmacokinetic and photoaffinity labeling studies.
Politi PM; Arnold ST; Felsted RL; Sinha BK
Mol Pharmacol; 1990 Jun; 37(6):790-6. PubMed ID: 1972771
[TBL] [Abstract][Full Text] [Related]
13. Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines.
Devy J; Wargnier R; Pluot M; Nabiev I; Sukhanova A
Anticancer Res; 2004; 24(3a):1745-51. PubMed ID: 15274350
[TBL] [Abstract][Full Text] [Related]
14. Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells.
Chen G; Teicher BA; Frei E
Anticancer Res; 1996; 16(6B):3499-505. PubMed ID: 9042212
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines.
Slovak ML; Hoeltge GA; Dalton WS; Trent JM
Cancer Res; 1988 May; 48(10):2793-7. PubMed ID: 2896069
[TBL] [Abstract][Full Text] [Related]
16. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH.
Gabr A; Kuin A; Aalders M; El-Gawly H; Smets LA
Cancer Res; 1997 Nov; 57(21):4811-6. PubMed ID: 9354443
[TBL] [Abstract][Full Text] [Related]
17. Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan.
Danks MK; Garrett KE; Marion RC; Whipple DO
Cancer Res; 1996 Apr; 56(7):1664-73. PubMed ID: 8603418
[TBL] [Abstract][Full Text] [Related]
18. DNA repair enzyme, O6-methylguanine DNA methyltransferase, modulates cytotoxicity of camptothecin-derived topoisomerase I inhibitors.
Kuo CC; Liu JF; Chang JY
J Pharmacol Exp Ther; 2006 Feb; 316(2):946-54. PubMed ID: 16258022
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells.
Kotoh S; Naito S; Yokomizo A; Kumazawa J; Asakuno K; Kohno K; Kuwano M
Cancer Res; 1994 Jun; 54(12):3248-52. PubMed ID: 8205547
[TBL] [Abstract][Full Text] [Related]
20. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]